Health ❯ Patient Care

Treatment Efficacy

Survival Rates Clinical Outcomes Drug Response Adverse Events Quality of Life Clinical Studies Drug Combinations Weight Management Safety Profiles Clinical Remission Side Effects Adverse Reactions

IDEAYA Combo Doubles Progression-Free Survival in Uveal Melanoma Trial

The results position darovasertib plus crizotinib for an FDA submission in the second half of 2026.

Pfizer’s Monthly Obesity Shot Shows Mid-Stage Gains With Up to 12.3% Weight Loss

Eupraxia Reports Early EoE Trial Data With Near‑Normal Tissue at Top Dose

Pluvicto Added to Standard Care Extends rPFS in PSMA-Positive Metastatic Hormone-Sensitive Prostate Cancer

FDA Approves Papzimeos as First Therapy for Adult Recurrent Respiratory Papillomatosis

Nektar Therapeutics’ Rezpegaldesleukin Trial Success Sends Shares Up 150%